期刊文献+

艾司西酞普兰治疗抑郁症的疗效和安全性 被引量:7

Efficacy and safety of escitalopram in treatment of depressive disorder
原文传递
导出
摘要 目的评价国产艾司西酞普兰治疗抑郁症的疗效和安全性。方法本研究为多中心、开放性研究,共入组符合CCMD-3诊断标准的抑郁症患者238例,服用国产艾司西酞普兰片10~20 mg·d^(-1),疗程为6 wk。使用汉密尔顿抑郁量表17项(HAMD-17)、临床疗效总评量表(CGI,包括病情严重程度CGI-S、疗效总评CGI-I)分别在治疗wk 1、2、4、6末进行疗效评价,使用不良事件记录表并根据症状、体征、实验室和心电图检查结果评价药物安全性。结果共计232例完成研究,在各时点HAMD-17(P<0.01)、CGI-S(P<0.05)、CGI-I(P<0.01)的总分与治疗前比较,均有显著差异。总体有效率为82.8%,痊愈率为58.6%。不良反应发生率为11.2%,整体耐受性较好。结论国产艾司西酞普兰是一种安全、有效的抗抑郁药物。 AIM To evaluate the clinical efficacy and safety of domestic escitalopram in the treatment of depression. METHODS Two hundred and thirty-eight patients met with CCMD-3 criteria of depressive disorder were included into the open, multicenter, six-week research with flexible dosages 10 - 20 mg. d-1 of escitalopram. The HAMD-17, CGI, adverse event rating scale and related laboratory examinations were used to assess the efficacy and safety of the treatment by the end of 1, 2, 4, 6 wk. RESULTS Two hundred and thirty-two patients completed the study. Results indicated a significant reduction in scores of HAMD-17 (P 〈 0.01 ), CGI- S (P 〈 0.05) and CGI-I (P 〈 0.01) in every treatment time points compared with those in baseline. The effective rate and cure rate was 82.8% and 58.6%, respectively. The adverse reaction rate was 11.2%, and all adverse reactions were well tolerated. CONCLUSION Generic escitalopram is an effective and safe antidepressant.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2011年第12期907-911,共5页 Chinese Journal of New Drugs and Clinical Remedies
关键词 抑郁症 艾司西酞普兰 治疗结果 安全 depressive disorder escitalopram treatment outcome safety
  • 相关文献

参考文献19

  • 1MONTGOMERY SA.Clinically relevant effect sizes in depression [J].Eur Neuropsychopharcol,1994,4(4):283-284.
  • 2Anon.Practice guideline for the treatment of patients with major depressive disorder(revision).American Psychiatric Association [J].Am J Psychiatry,2000,157(4 Suppl):1-45.
  • 3SORBERA LA,MARTIN L,REVEL L,et al.Escitalopram oxalate[J].Drugs Fut,2001,26(2):115-120.
  • 4赖树清.抗抑郁药 草酸s-西酞普兰(escitalopram oxalate)[J].世界临床药物,2003,24(12):762-763. 被引量:8
  • 5SANCHEZ C,KREILGAARD M.R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram[J].Pharm Biochem Behav,2004,77(2):391-398.
  • 6OWENS MJ,KNIGHT DL,NEMEROFF CB.Second-generation SSRIs:human monoamine transporter binding profile of escitalopram and R-fluoxetine[J].Biol Psychiatry,2001,50(5):345-350.
  • 7von MOLTKE LL,GREENBLATT DJ,GIANCARLO GM,et al. Escitalopram(Scitalopram) and its metabolites in vitro:cytochromes mediating biotransformation,inhibitory effects,and comparison to R-citalopram[J].Drug Metab Dispos,2001,29 (9):1102-1109.
  • 8YEVTUSHENKO VY,BELOUS AI,YEVTUSHENKO YG, et al.Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder:A 6-week,multicenter,prospective, randomized,double-blind,activecontrolled study in adult outpatients[J].Clin Ther 2007,29(11):2319-2332.
  • 9MOORE N,VERDOUX H,FANTINO B.Prospective,multicentre, randomized,double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder[J].Int Clin Psychopharmacol,2005,20(3): 131-137.
  • 10COLONNA L,ANDERSEN HF,REINES EH.A randomized, double blind,24-week study of escitalopram(10 mg/day) versus citalopram(20 mg/day) in primary care patients with major depressive disorder[J].Curr Med Res Opin,2005,21(10): 1659-1668.

二级参考文献14

  • 1姚忠科,阚丽娟.草酸依地普仑的合成[J].中国新药杂志,2006,15(2):117-120. 被引量:2
  • 2张丽霞,薛强.紫外分光光度法测定草酸右旋依地普仑片的溶出度[J].中国药房,2007,18(4):297-298. 被引量:3
  • 3OWENS M J, KNIGHT DL, NEMEROFF CB. Second-generation SSRIs : human monoamine transporter binding profile of escitalopram and R-fluoxetine[J]. Biol Psychiatry, 2001, 50(5): 345- 350.
  • 4MURDOCH D, KEAM SJ. Escitalopram: a review of its use in the management of major depressive disorder[J]. Drugs, 2005, 65 (16) : 2379-2404.
  • 5BAUMANN P, ZULLINO DF, EAP CB. Enantiomer's potential in psychopharmacology: a critical analysis with special emphasis on the antidepressant escitalopram[J]. Eur Neuropsychopharmacol, 2002, 12(5) : 433-444.
  • 6CHEN F, LARSEN MB, SANCHEZ C, et al. The S-enantiomer of R, S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors [J]. Eur Neuropsychopharmacol, 2005, 15(2): 193-198.
  • 7MORK A, KREILGAARD M, SANCHEZ C. The R-enantiomer of citalopram counteracts escitalopram induced increase in extracellular 5-HT in the frontal cortex of freely moving rats [J]. Neuropharmacology, 2003, 45(2) : 167-173.
  • 8SANCHEZ C, GRUCA P, PAPP M. R-citalopram counte-racts the antidepressant-like effect of escitalopram in a rat chronic mild stress model[J]. Behav Pharmacol, 2003, 14(5-6): 465- 470.
  • 9SANCHEZ C, BERGQVIST PB, BRENNUM LT, et al. Escitalopram, the S-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities[J]. Psychopharmacology (Berl), 2003, 167(4): 353-362.
  • 10KENNEDY SH, ANDERSEN HF, LAM RW. Efficacy of eseitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitions and venlafaxine XR: a meta-analysis[J]. J Psychiatry Neurosci, 2006, 31(2) : 122-131.

共引文献27

同被引文献69

  • 1袁勇贵,张石宁.文拉法辛对选择性5-羟色胺再摄取抑制剂治疗无效的抑郁症患者的疗效[J].中华精神科杂志,2005,38(1):27-29. 被引量:37
  • 2刘文,李焕德.新型抗抑郁药物的临床应用及其作用机制研究进展[J].中国药房,2007,18(1):66-68. 被引量:30
  • 3江开达,苏晖,徐一峰,李飞,刘晓华,刘义兰,潘桂花.文拉法辛缓释剂和氟西汀治疗首发抑郁症的对照研究[J].上海精神医学,2007,19(1):15-18. 被引量:7
  • 4中华医学会精神科分会.中国精神障碍分类与诊断标准(第三版)[M].济南:山东科学技术出版社,2001.75-8.
  • 5汪向东,王希林,马弘.心理卫生评定量表手册[M].北京:中国心理卫生杂志社,2001:161-167.
  • 6Baldwin DS, Anderson IM, Nutt D J, et al. Evidence - based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology [J]. J Psychopharmacol, 2005,19 (6) :567 - 596.
  • 7Culpepper I,. Identifying and treating panic disorder in primary care[J]. Clin Psychiatry, 2004,65 (Suppl 5 ) : 19 - 23.
  • 8刘协和.精神病学[M].第4版.北京:人民卫生出版社,2001:457-461.
  • 9Demyttenanere K, Bruffaerts R, Posada - Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the world health organiza- tion world mental health surveys[J]. JAMA,2004,291 (21 ) :2 581 - 2 590.
  • 10Royal Australian and New Zealand College of Psychiatrists Clinical Prac- tice Guidelines Team for Panic Disorder and Agoraphobia. Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia[J]. Aust NZ J Psychiatry,2003,37(6) :641 -656.

引证文献7

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部